ACRV on Nasdaq
Acrivon Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $60.0M | $64.0M |
| General and administrative | $24.1M | $25.2M |
| Total operating expenses | $84.1M | $89.2M |
| Loss from operations | -$84.1M | -$89.2M |
| Interest income | $6.5M | $9.2M |
| Other expense, net | -$270.0K | -$558.0K |
| Total other income, net | $6.2M | $8.6M |
| Net loss | -$77.9M | -$80.6M |
| Net loss per sharebasic | -$2.02 | -$2.38 |
| Net loss per sharediluted | -$2.02 | -$2.38 |
| Weighted-average common stock outstandingbasic | 38.5M shares | 33.8M shares |
| Weighted-average common stock outstandingdiluted | 38.5M shares | 33.8M shares |
| Unrealized (loss) gain on available-for-sale investments, net of tax | -$336.0K | $530.0K |
| Comprehensive loss | -$78.2M | -$80.0M |
Every line of the balance sheet in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $41.5M | $39.8M | |
| Short-term investments | $77.1M | $139.7M | |
| Prepaid expenses and other current assets | $1.9M | $2.1M | |
| Total current assets | $120.4M | $181.6M | |
| Property and equipment, net | $4.9M | $4.5M | |
| Operating lease right-of-use assets | $2.5M | $3.6M | |
| Long-term investments | $5.1M | ||
| Restricted cash | $203.0K | $198.0K | |
| Other assets | $1.7M | $1.6M | |
| Total assets | $129.7M | $196.6M | |
| Accounts payable | $2.3M | $758.0K | |
| Accrued expenses and other current liabilities | $12.2M | $15.4M | |
| Operating lease liabilities, current | $1.2M | $1.1M | |
| Total current liabilities | $15.7M | $17.2M | |
| Operating lease liabilities, non-current | $1.5M | $2.6M | |
| Total liabilities | $17.2M | $19.8M | |
| Common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2025 and 2024; 31,648,856 and 31,231,264 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $31.0K | $31.0K | |
| Additional paid-in capital | $387.3M | $373.3M | |
| Accumulated other comprehensive income | $111.0K | $447.0K | |
| Accumulated deficit | -$274.9M | -$197.0M | |
| Total stockholders' equity | $112.5M | $176.8M | $121.2M |
| Total liabilities and stockholders' equity | $129.7M | $196.6M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares, issued | 0 shares | 0 shares | |
| Preferred stock, shares, outstanding | 0 shares | 0 shares | |
| Common stock, per share value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares, issued | 31.6M shares | 31.2M shares | |
| Common stock, shares, outstanding | 31.6M shares | 31.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$77.9M | -$80.6M |
| Depreciation expense | $1.4M | $1.0M |
| Stock-based compensation expense | $14.7M | $14.3M |
| Non-cash operating lease expense | $1.0M | $932.0K |
| Net amortization of premiums and accretion of discounts on investments | -$437.0K | -$3.8M |
| Prepaid expenses and other current assets | $190.0K | $237.0K |
| Accounts payable | $1.5M | -$3.6M |
| Accrued expenses and other liabilities | -$3.4M | $8.0M |
| Operating lease liabilities | -$936.0K | -$1.1M |
| Other assets | $137.0K | -$1.2M |
| Net cash used in operating activities | -$63.7M | -$65.7M |
| Purchases of investments | -$81.7M | -$202.9M |
| Proceeds from maturities of investments | $149.5M | $153.9M |
| Purchases of property and equipment | -$1.7M | -$2.8M |
| Net cash provided by (used in) investing activities | $66.1M | -$51.8M |
| Proceeds from issuance of common stock in private placement | $70.0M | |
| Proceeds from issuance of pre-funded warrants in private placement | $60.0M | |
| Proceeds from exercise of stock options | $1.0K | $90.0K |
| Payments of offering costs | -$6.5M | |
| Payments of tax withholdings related to vesting of restricted stock units | -$750.0K | -$2.5M |
| Net cash (used in) provided by financing activities | -$749.0K | $121.0M |
| Net increase in cash, cash equivalents, and restricted cash | $1.7M | $3.6M |
| Deferred offering costs in accrued expenses and other current liabilities | $143.0K | |
| Purchases of property and equipment included in accounts payable | $17.0K | |
| Right-of-use assets obtained in exchange for operating lease liability | $56.0K |
Recent filings
- Oct 7, 20264
- Sep 2, 20263
- Sep 2, 20264
- Aug 27, 20264
- Aug 25, 2026144
- Aug 20, 20264
- Aug 20, 20264
- Aug 20, 20264
- Aug 20, 20264
- Aug 20, 20264
- Aug 13, 2026SCHEDULE 13G/A
- Aug 12, 202610-Q
- Aug 12, 20268-K
- Aug 12, 2026S-8
- Aug 6, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8